RheumNow Podcast – Pounds of Prevention (3.5.2021)
Mar 04, 2021
Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.
Read Article
News Feature: MAXIMISE Trial - Secukinumab Efficacy in Psoriatic Spondylitis Patients
https://t.co/34RU4OSaRi
Links:
Dr. John Cush @RheumNow( View Tweet )
Feb 28, 2021
MAXIMISE Trial - Secukinumab Efficacy in Psoriatic Spondylitis Patients
Feb 26, 2021
The results of the novel MAXIMISE trial have been published, demonstrating that secukinumab significantly improved axial signs and symptoms in psoriatic arthritis patients with axial manifestations with inadequate NSAID response.
Read Article
We are three weeks out from RheumNow Live. Are you planning on attending?
https://t.co/vJlU0Z3Q3x
Links:
Dr. John Cush @RheumNow( View Tweet )
Feb 26, 2021
RheumNow Podcast – Sweet Lies or Hard Truths? (2.26.2021)
Feb 26, 2021
Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.
Read Article
Psoriasis has greatest risk of MTX liver dz - a Danish Population study of PsO, PsA & RA pts taking MTX. Risk of liver Dz was most in PsO, followed by PsA, then RA. PsO had 1.6-3.4 fold risk (mild-severe) liver dz (vs RA). PsA was 1.3-1.6x higher) https://t.co/9YiGqVr66w
Links:
Dr. John Cush @RheumNow( View Tweet )
Feb 25, 2021
RWCS Highlights - Day 3
-Psoriatic Arthritis
-Evidence Based Medicine: Diet and Rheumatic Diseases
-Hot topics in Allergy/Immunology
-Pediatric Rheumatology – past, present, and future
https://t.co/CaKAyhxId3 https://t.co/5m882bcTOo
Links:
Dr. John Cush @RheumNow( View Tweet )
Feb 16, 2021
RWCS Highlights - Day 3
Feb 15, 2021
Day 3 report from the 2021 RWCS meeting in Maui (and virtually) includes pearls from the PsA 2020 Year in Review; fact vs. fiction on evidence based medicine: diet and rheumatic diseases; hot topics in allergy/immunology; and pediatric rheumatology highlights.
Read Article
EXCEED study in #PsA shows lower responses in women (vs men) treated with either secukinumab or adalimumab. Question is, why? @RWCSmtg @JointMD https://t.co/LFBQi1jtiu
Dr. John Cush @RheumNow( View Tweet )
Feb 12, 2021
In #PsA does it matter if you're on background MTX when treated with ixekizumab or adalimumab? MTX does augment ADA responses but it's not needed with IXE @RWCSmtg @JointMD https://t.co/9GpKjLS4ao
Dr. John Cush @RheumNow( View Tweet )
Feb 12, 2021
No increased risk of cancer with TNFi use in PsA patients @RWCSmtg @JointMD https://t.co/7VSI1Fd1hw
Dr. John Cush @RheumNow( View Tweet )
Feb 12, 2021
Partial control of #PsA on MTX- Control study shows that adding adalimumab is superior to just escalating MTX @RWCSmtg @JointMD https://t.co/nDWzf4HYwp
Dr. John Cush @RheumNow( View Tweet )
Feb 12, 2021
Drs. Kavanaugh, Ruderman, Ogdie at @RWCSmtg on the multiple domains of psoriatic arthritis #PsA @JointMD https://t.co/3uS6JxdfIR
Dr. John Cush @RheumNow( View Tweet )
Feb 12, 2021
Weekly Semaglutide for Weight Loss in Adults
Feb 11, 2021
NEJM has reported the results of a trial showing semaglutide once weekly plus lifestyle intervention was associated with sustained, weight loss in overweight or obese adults; such that nearly one-third lost over 20% of their body weight.
Semaglutide, a once weekly glucagon-like
Read Article
ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients
Feb 10, 2021
The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease patients, based on the efforts of the North American Task force. The document provides guidance to rheumatology providers on the use of the
Read Article
We are excited to announce that Dr. Eric Ruderman ( @JointMD) will be speaking on advancing treatments in psoriatic arthritis at RheumNow Live, March 20-21. There's still time to sign up. https://t.co/vJlU0Z3Q3x https://t.co/T0V8JIygyA
Links:
Dr. John Cush @RheumNow( View Tweet )
Feb 09, 2021
Comorbidity and Drugs Drive COVID-19 Severity and Survival in Rheumatic Disease
Feb 09, 2021
While comorbidities are associated with severe COVID-19 infection, it appears they also influence severity and survival in rheumatic disease (RMD), according to a a French cohort study,
Analysis of a French RMD cohort with SARS-CoV-2 infection analyzed the effect of inflammatory
Read Article
QD Clinic Podcast from Last week. iTunes https://t.co/FHJv01AAbC or SoundCloud https://t.co/dfSTkSbY2d
QD Clinics (123-127; Feb 5)
QD127 - Chronic Monarthritis
QD126 - Fever by the Numbers
QD125 - "What Were You Thinking"
QD124 - No Win Consults
QD123 - When RA Meets UC https://t.co/ReOFOVooje
Dr. John Cush @RheumNow( View Tweet )
Feb 08, 2021
RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)
Feb 05, 2021
Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.
Read Article
Consults in Cars--have telehealth consults gone too far?
https://t.co/INbKZ3xxty https://t.co/X2RwktCd2U
Links:
Dr. John Cush @RheumNow( View Tweet )
Feb 03, 2021
Low Persistence of Biologics in Psoriatic Arthritis
Feb 02, 2021
A longitudinal observational cohort study of psoriatic arthritis (PsA) patients treated with biologic therapy finds relatively low persistence of selected biologic therapy in PsA patients
Analysis of PsA patients (n=2301) from a large healthcare provider database, seen between 2002
Read Article
Low Persistence of Biologics in Psoriatic Arthritis
A longitudinal observational cohort study of psoriatic arthritis (PsA) patients treated with biologic therapy finds relatively low persistence of selected biologic therapy in PsA patients.
https://t.co/CzQnpAnttW https://t.co/uYU778rwod
Links:
Dr. John Cush @RheumNow( View Tweet )
Feb 02, 2021
Abbvie has released data from KEEPsAKE-1 and KEEPsAKE-2 studies (1407 pts) showing Risankizumab (IL--23 inhibitor) is effective in Psoriatic arthritis; RIS Rx pts achieved ACR20 of 57% and 51% at week 24 (vs PBO 34% and 27%; p<0.001) https://t.co/wPQMqLnhOO
Links:
Dr. John Cush @RheumNow( View Tweet )
Feb 01, 2021
Sign up for RheumNow Live, March 20 and 21st. CME credits available.
https://t.co/uwxOVh142F https://t.co/GqkCLBGl62
Links:
Dr. John Cush @RheumNow( View Tweet )
Jan 31, 2021
Several studies have shown that Xray progression has lessened in recent yrs - presumeably from more aggressive Rx by Rheums! Still - Predictors of Xray long term damage = high ESR/CRP, baseline xray damage, -CCP/RF positivity https://t.co/2iaMiaquEV https://t.co/cgEP4QBvL4
Dr. John Cush @RheumNow( View Tweet )
Jan 29, 2021
Recent Blogs
Staying Abreast of COVID-19
Mar 24, 2020
